/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biopharmaceutical company advancing T cell engaging ( TCE ) bispecific antibodies ( bsAb ) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 ( CLDN6 ) x CD3 TCE, CT-95, a Mesothelin ( MSLN ) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 ( Nectin-4 ) x CD3 TCE.
$0.37
$0.01 (-3.89%)
EOD Sep 18, 2026
Negative free cash flow of -$26M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$46M
▼ -35.2% YoY
Op. Margin
—
ROIC
-68.52%
▲ +3.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$34M
▼ -81.4% YoY
Op. Cash Flow (TTM)
-$34M
▼ -81.3% YoY
Net Debt
-$43M
Net Cash Position
Cash & Equiv.
$43M
Continue Research
SourceComputed from the 10-Q filed 5 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 6 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.